Skip to content
EveryOption

Sertraline

Learn what this care may do. See what research says. Then check where to get care. A place may not be taking new patients.

See published Need uses

Identity

Sertraline (brand name ZOLOFT) is a prescription medicine. Its U.S. product labeling lists obsessive-compulsive disorder (OCD) among the conditions it is indicated to treat.

DailyMed sertraline (Zoloft) label · checked Oct 16, 2026

Relationship: supports

Statement scope

Formulation or format

tablet, film coated; oral solution

Indication

obsessive-compulsive disorder

Population

patients with obsessive-compulsive disorder as labeled

Section code

34067-9

Source collection coverage: country:US

Pointer: /sections/1

Open source

Why-linked

EveryOption includes sertraline for OCD because the DailyMed ZOLOFT label’s Indications and Usage section names OCD as a labeled indication. That label statement was checked against this source. A clinical evidence assessment of how well sertraline works for OCD has not yet been published here.

DailyMed sertraline (Zoloft) label · checked Oct 16, 2026

Relationship: supports

Statement scope

Formulation or format

tablet, film coated; oral solution

Indication

obsessive-compulsive disorder

Population

patients with obsessive-compulsive disorder as labeled

Section code

34067-9

Source collection coverage: country:US

Pointer: /sections/1

Open source

Indication-quote

• Obsessive-compulsive disorder (OCD)

DailyMed sertraline (Zoloft) label · checked Oct 16, 2026

Relationship: supports

Statement scope

Formulation or format

tablet, film coated; oral solution

Indication

obsessive-compulsive disorder

Population

patients with obsessive-compulsive disorder as labeled

Section code

34067-9

Source collection coverage: country:US

Pointer: /sections/1

Open source

Scope

This page explains why the option appears and what the cited label supports. It does not set dosing, compare treatments, or report availability. Access information is not shown here.

DailyMed sertraline (Zoloft) label · checked Oct 16, 2026

Relationship: supports

Statement scope

Formulation or format

tablet, film coated; oral solution

Indication

obsessive-compulsive disorder

Population

patients with obsessive-compulsive disorder as labeled

Section code

34067-9

Source collection coverage: country:US

Pointer: /sections/1

Open source

Provenance

Cited source: DailyMed (U.S. National Library of Medicine) structured product label for ZOLOFT (sertraline hydrochloride), SET ID fda754f6-d0f3-4dce-a17a-927d64f912f7, version 7, Indications and Usage. Hosting on DailyMed is not a license to republish the full label.

DailyMed sertraline (Zoloft) label · checked Oct 16, 2026

Relationship: supports

Statement scope

Formulation or format

tablet, film coated; oral solution

Indication

obsessive-compulsive disorder

Population

patients with obsessive-compulsive disorder as labeled

Section code

34067-9

Source collection coverage: country:US

Pointer: /sections/1

Open source

Published scope

EveryOption currently publishes Sertraline research for bulimia nervosa, major depressive disorder, obsessive-compulsive disorder, and panic disorder. Each exact Need page states its source and limits. This is not a complete list of uses.

PubMed Central open-access full text · checked Oct 16, 2026

Relationship: supports published treatment scope

Statement scope

Completeness

Not assessed

Need

bulimia nervosa

Population

outpatients with bulimia nervosa as described by the evidence review

Source collection coverage: global

Pointer: /document/passage

Open source
DailyMed sertraline (Zoloft) label · checked Oct 16, 2026

Relationship: supports published treatment scope

Statement scope

Completeness

Not assessed

Need

Panic Disorder

Population

source-defined population

Source collection coverage: country:US

Pointer: /sections/2

Supporting passage: The effectiveness of ZOLOFT in the treatment of PD was demonstrated in three double‑blind, placebo‑controlled studies (Studies PD-1, PD-2, and PD‑3) of adult outpatients who had a primary diagnosis of PD (DSM‑III‑R), with or without agoraphobia.

Open source
DailyMed sertraline (Zoloft) label · checked Oct 16, 2026

Relationship: supports published treatment scope

Statement scope

Formulation or format

tablet, film coated; oral solution

Indication

obsessive-compulsive disorder

Population

patients with obsessive-compulsive disorder as labeled

Section code

34067-9

Source collection coverage: country:US

Pointer: /sections/1

Open source
DailyMed sertraline (Zoloft) label · checked Oct 16, 2026

Relationship: supports published treatment scope

Statement scope

Completeness

Not assessed

Need

Major Depressive Disorder

Population

source-defined population

Source collection coverage: country:US

Pointer: /sections/1

Supporting passage: The efficacy of ZOLOFT as a treatment for MDD was established in two randomized, double-blind, placebo-controlled studies and one double-blind, randomized-withdrawal study following an open label study in adult (ages 18 to 65) outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) criteria for MDD (studies MDD-1 and MDD-2).

Open source
Published Sep 21, 2026Revision 5 · EveryOptionEnglish (United States)

Published Need uses

Select an exact Need to inspect its scoped research. These are the uses currently published on EveryOption; they do not establish every use of Sertraline or a personal recommendation.

4 published uses

Sertraline for Major Depressive Disorder

The research answer belongs to this exact Need and its published scope. It does not establish benefit for other uses of Sertraline.

Research suggests benefit in this exact scope

Published Sep 20, 2026 · revision 1

What research says

The current ZOLOFT label reports randomized, double-blind, placebo-controlled studies supporting its MDD evidence scope. This bounded assessment does not compare every option or determine personal suitability.

DailyMed sertraline (Zoloft) label · checked Oct 16, 2026

Relationship: supports bounded conclusion

Statement scope

Completeness

Not assessed

Need

Major Depressive Disorder

Population

source-defined population

Source collection coverage: country:US

Pointer: /sections/1

Supporting passage: The efficacy of ZOLOFT as a treatment for MDD was established in two randomized, double-blind, placebo-controlled studies and one double-blind, randomized-withdrawal study following an open label study in adult (ages 18 to 65) outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) criteria for MDD (studies MDD-1 and MDD-2).

Open source
DailyMed sertraline (Zoloft) label · checked Oct 16, 2026

Relationship: label-reported clinical studies for the Need

Statement scope

Completeness

Not assessed

Need

Major Depressive Disorder

Population

source-defined population

Source collection coverage: country:US

Pointer: /sections/1

Supporting passage: The efficacy of ZOLOFT as a treatment for MDD was established in two randomized, double-blind, placebo-controlled studies and one double-blind, randomized-withdrawal study following an open label study in adult (ages 18 to 65) outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) criteria for MDD (studies MDD-1 and MDD-2).

Open source
Read exact answerExplore Major Depressive Disorder options

Sertraline for Panic Disorder

The research answer belongs to this exact Need and its published scope. It does not establish benefit for other uses of Sertraline.

Research suggests benefit in this exact scope

Published Sep 20, 2026 · revision 1

What research says

The current ZOLOFT label reports three double-blind, placebo-controlled studies in adult outpatients with panic disorder. This bounded assessment does not compare every option or determine personal suitability.

DailyMed sertraline (Zoloft) label · checked Oct 16, 2026

Relationship: supports bounded conclusion

Statement scope

Completeness

Not assessed

Need

Panic Disorder

Population

source-defined population

Source collection coverage: country:US

Pointer: /sections/2

Supporting passage: The effectiveness of ZOLOFT in the treatment of PD was demonstrated in three double‑blind, placebo‑controlled studies (Studies PD-1, PD-2, and PD‑3) of adult outpatients who had a primary diagnosis of PD (DSM‑III‑R), with or without agoraphobia.

Open source
DailyMed sertraline (Zoloft) label · checked Oct 16, 2026

Relationship: label-reported clinical studies for the Need

Statement scope

Completeness

Not assessed

Need

Panic Disorder

Population

source-defined population

Source collection coverage: country:US

Pointer: /sections/2

Supporting passage: The effectiveness of ZOLOFT in the treatment of PD was demonstrated in three double‑blind, placebo‑controlled studies (Studies PD-1, PD-2, and PD‑3) of adult outpatients who had a primary diagnosis of PD (DSM‑III‑R), with or without agoraphobia.

Open source
Read exact answerExplore Panic Disorder options

Sertraline for Bulimia Nervosa

The research answer belongs to this exact Need and its published scope. It does not establish benefit for other uses of Sertraline.

Promising, with important evidence limits

Published Sep 21, 2026 · revision 1

What research says

An open-access evidence review reports one 12-week placebo-controlled study in outpatients with bulimia nervosa that found fewer binge-eating crises and purging episodes with sertraline; one older study is promising but limited evidence. This assessment does not compare every option or determine personal suitability.

PubMed Central open-access full text · checked Oct 16, 2026

Relationship: supports bounded conclusion

Statement scope

Completeness

Not assessed

Need

bulimia nervosa

Population

outpatients with bulimia nervosa as described by the evidence review

Source collection coverage: global

Pointer: /document/passage

Open source
PubMed Central open-access full text · checked Oct 16, 2026

Relationship: small trial of sertraline for bulimia nervosa

Statement scope

Completeness

Not assessed

Need

bulimia nervosa

Population

outpatients with bulimia nervosa as described by the evidence review

Source collection coverage: global

Pointer: /document/passage

Open source
Read exact answerExplore Bulimia Nervosa options

Sertraline for Obsessive-Compulsive Disorder

The research answer belongs to this exact Need and its published scope. It does not establish benefit for other uses of Sertraline.

Not reviewed. No current published assessment exists for this exact Treatment and Need. This does not establish benefit or no benefit.

DailyMed sertraline (Zoloft) label · checked Oct 16, 2026

Relationship: labeled indication

Statement scope

Formulation or format

tablet, film coated; oral solution

Indication

obsessive-compulsive disorder

Population

patients with obsessive-compulsive disorder as labeled

Section code

34067-9

Source collection coverage: country:US

Pointer: /sections/1

Open source
Read exact answerExplore Obsessive-Compulsive Disorder options

Next: check access

Research and local availability are different facts. Add a place to see known, source-backed access options for Sertraline.

Find access

See something wrong? Tell us. Your note is private. We check sources before we change this page.